Omniscient Neurotechnology, a pioneer in AI-driven brain analysis, has secured $27.2 million (AU$41.1 million) in an oversubscribed Series D funding round. The round is co-led by OIF Ventures and the Australian National Reconstruction Fund Corporation (NRFC), with continued support from long-term investors including Will Vicars and Gina Rinehart AO.
Funding to Scale Quicktome Platform
The capital will accelerate commercial expansion of Omniscient's FDA-cleared Quicktome platform and the development of new clinical applications, extending the company's reach into high-growth markets like brain computer interface (BCI), stroke, and movement disorders.
Connectomics Technology
Omniscient's connectomics technology uses AI to decode the wiring of each individual's brain. The Quicktome platform generates patient-specific connectomic maps that visualize functional regions and neural pathways responsible for language, movement, and cognition. These insights help clinicians avoid neurologic complications and improve outcomes across the neuro care continuum.
"AI lets us turn the vast complexity of the human brain into clear, actionable intelligence," said Stephen Scheeler, CEO of Omniscient. "This funding scales that capability, bringing AI-driven precision brain medicine to patients, physicians, and partners in the US and worldwide."
Reimbursement Breakthrough
The funding round follows a major reimbursement breakthrough: CPT code 1039T, which establishes a billing pathway for connectomic analysis and drives adoption across the US healthcare system.
Strategic Pillars
The Series D funding will support two strategic pillars:
- Accelerating Market Penetration: scaling specialized sales and clinical support staff to service a fast-growing roster of major US healthcare networks.
- Expanding Market Reach: fueling the development of next-generation brain AI tools to reach untapped markets.
"Omniscient's platform is a rare deep-tech breakthrough," said David Shein, Partner at OIF Ventures. "We're backing the team to scale this 'Google Maps for the Brain' into a global standard of care."
About Omniscient
Omniscient is a world leader in applying AI to decode the human brain through connectomics. Its mission is to improve the lives of billions by advancing brain health. The Quicktome platform delivers critical insights across neurologic conditions, from cranial surgery and neuro-oncology to stroke, mental illness, and beyond. Looking ahead, Omniscient is poised to transform care for Alzheimer's, Parkinson's, depression, and other conditions through personalized brain medicine.
